BARACK-D: Benefits of aldosterone receptor antagonism in chronic kidney disease
- Status:: In follow-up
This is a prospective randomised open blinded endpoint trial to determine the effect of aldosterone receptor antagonism on mortality and cardiovascular outcomes in patients with stage 3b chronic kidney disease.
Chronic kidney disease (CKD) is increasingly common, affecting around 10% of the entire population, associated with an age-related decline in renal function that is accelerated in hypertension, diabetes mellitus, obesity and primary renal disorders. While this high (and rising) prevalence is in part due to the ageing population, it is also a result of increases in hypertension and diabetes mellitus as well as a variety of primary renal disorders. The most important component of CKD in terms of mortality and morbidity is cardiovascular disease (CVD). Better treatment options to provide protection from vascular events or delay progression of CKD are therefore urgently needed, especially given the increasing burden of the disease.
|Study Design:||A prospective randomised open blinded endpoint trial|
|Sponsor:||University of Oxford|
|Ethical Approval:||EudraCT Number: 2012-002672-13|
|Chief Investigator:||Professor Richard Hobbs, University of Oxford|